Thus, further investigation of ways to increase mGluR5 associated glutamatergic functionality (and consecutively the NMDA‐receptor activity) may be a promising approach for the treatment of negative symptoms in schizophrenia. This evidence concerns the gene GRM5 and schizophrenia.